Table II. Prevalences and incidences of neuromyelitis optica spectrum stratified by age and sex in studies conducted according to the 2015 diagnostic criteria.
|
|
Population (million inhab)
(age groups and sex)
|
Prevalence/105 inhab
(95% CI)
|
Incidence/ 105 persons/year
(95% CI)
|
Catalonia (Spain), 2018
|
18-39
|
Women
|
1.36 (1.29-1.43)
|
0.131 (0.065-0.197)
|
Men
|
0.28 (0.2 -0.32)
|
0.016 (−0.006-0.039)
|
40-59
|
Women
|
1.79 (1.71-1.87)
|
0.126 (0.057-0.194)
|
Men
|
0.7 (0.65-0.5)
|
0.057 (0.011-0.103)
|
> 60 years
|
Women
|
1.39 (1.32- 1.47)
|
0.032 (−0.004-0.068)
|
Men
|
0.64 (0.58-0.69)
|
0.041 (−0.005-0.088)
|
Hungary, 2020
|
18-39
|
Women
|
2.95 (2.04-4.12)
|
2.35 (1.6-3.34)
|
Men
|
0.5 (0.18-1.08)
|
0.22 (0.045-0.64)
|
40-59
|
Women
|
4.77 (3.55-6.27)
|
3.5 (2.47-4.8)
|
Men
|
0.58 (0.21-1.26)
|
0.59 (0.22-1.28)
|
> 60 years
|
Women
|
2.07 (1.33-3.08)
|
1.64 (0.95-2.62)
|
Men
|
0.26 (0.03-0.94)
|
0.3 (0.036-1.08)
|
CI: confidence interval; inhab: inhabitants.
|
Finally, the few studies that provide data stratified by serostatus report higher prevalence figures in Asia than in Europe for anti-AQP4 patients. The prevalences of NMOSD patients with anti-AQP4 were 1.99 (95% CI: 1.09-3.35) and 3.2 (95% CI: not reported) in the studies from Japan and Penang Island, Malaysia [
25,
26], respectively, compared with prevalences of 0.76 (95% CI: 0.53-1.06), 1.2 (95% CI: 0.5-2.3) and 1.61 (95% CI: 1.31-1.95) per 100,000 inhabitants in the Danish, Hungarian and Oxfordshire studies, respectively [
21-
23]. The study conducted in Catalonia reported a progressive increase in the prevalence figures of patients with NMOSD with anti-AQP4 parallel to age, with a peak of 0.89 (95% CI: 0.85-0.92) per 100,000 inhabitants aged 40-59 years [
19] (Table II). This same study showed that anti-AQP4 is more prevalent in women than in men in all age ranges, especially in the 40-59 age range – women, 1.43 (95% CI: 1.36-1.5) versus men, 0.35 (95% CI: 0.32-0.39) [
19]. In contrast, if we focus on seronegative patients with NMOSD, the prevalence in men and women was similar for most age ranges [
19].
Regarding the incidence according to serostatus, only European studies are available. The incidences of NMOSD patients with anti-AQP4 were 0.05 (95% CI: 0.03-0.07) in Denmark [
21] and 1.15 (95% CI: 0.92-1.42) in Hungary [
22]. The study in Catalonia showed a progressive increase in the incidence of patients with NMOSD with anti-AQP4 parallel to age, which was 0.062 (95% CI: 0.028-0.096) per 100,000 persons/year in the range of 40-59 years [
19]. Again, the incidence was higher in women than in men in all the age groups [
19].
Epidemiology of neuromyelitis optica spectrum in Latin America
Main studies
Several studies have estimated prevalence or incidence figures for NMOSD in Latin America; however, as previously mentioned, there is currently only one that has used the 2015 diagnostic criteria to estimate prevalence [30]. It is a multicentre retrospective study conducted in the central and western regions of Venezuela (Table II). A total of 249 cases were identified using information from the medical records of the hospitals in the areas studied, which was then contrasted with that included in the registry of the National Multiple Sclerosis Programme to avoid duplicates. Regarding demographic characteristics, a higher proportion of women was observed (
n = 206; 82.7%). The population was young, with a mean age of 34 years, and the mixed race population was the most affected (
n = 206; 86.7%). On interpreting the results it should be noted that in Venezuela it is difficult to determine the presence of anti-AQP4 in all the patients studied, while it is currently not possible to determine anti-MOG. The estimated prevalence was 2.11 (95% CI: 1.85-2.37) cases of NMOSD per 100,000 inhabitants.
The pre-2015 study that may be most similar to the Venezuelan study is the one comparing incidence and prevalence in Martinique with that of Olmsted County, Minnesota, United States [
32]. In this study, the authors used 2006 criteria or selected patients with positive anti-AQP4 determination and one or more of the following syndromes that did not meet the 2006 criteria: simple or recurrent transverse myelitis, monophasic or recurrent optic neuritis, brainstem attack or cerebral (hemispheric) attack. Incidence was calculated using the periods 1
st January 2003 to 31
st December 2011, while prevalence was calculated as of 31 December 2011. It should be noted that these estimates were obtained by standardising by sex and age based on the total US population in 2010 and that four age groups were used (0-18, 19-39, 40-64 and 65 years and older). The demographic characteristics of the Martinique cases are very similar to those of the Venezuela study in terms of the proportion of women affected and age of onset, taking into account the different way of measuring age as the mean or median (Tables I and II). In the case of Martinique, however, the large proportion of Afro-Caribbean patients (
n = 38/39; 97%) stands out, which most likely explains the results. The incidence per 100,000 persons/year was 0.73 (95% CI: 0.45-1.01), while the prevalence per 100,000 inhabitants was 10 (95% CI: 6.8-13.2). These results contrast with those of the Olmsted County cases, with a predominantly Caucasian population (
n = 5/6; 83%), which demonstrated an incidence of 0.07 (95% CI: 0-0.21) per 100,000 persons/year and a prevalence of 3.9 (95% CI: 0.8-7.1) per 100,000 inhabitants.
Other studies in chronological order
In the following, in-depth details are given about the main studies carried out on the prevalence or incidence of NMOSD in Latin America. First, the demographics of Mexico will be discussed. Second, we will focus on the Caribbean basin, which includes the French islands of Martinique and Guadeloupe, and their comparison with the demographic data in Cuba. Subsequently, the Central American studies conducted in Panama and Costa Rica will be mentioned. Finally, we will detail the prevalence data in Brazil (Table III).
Table III. Latin American epidemiological studies on the prevalence and/or incidence of the neuromyelitis optica spectrum.
|
|
Period of study
|
Sources of the register
|
Cases of NMOSD, n (criteria)
|
Women, n (%)
|
Age at onset
|
Origin of patients with NMOSD, n (%)
|
Proportion of anti-AQP4 antibodies, n (%)
|
Antibody diagnostic technique
|
Incidence/105 persons/year (95% CI)
|
Prevalence/105 inhab (95% CI)
|
Martinique (versus Olmsted County, United States), 2016
|
2003-2011
|
Insurance records, neurology hospital registries and MS patients associations
|
39
(2006, other definitions)
|
36 (90)
|
35 (14-82)b
|
Negro: 38 (97)
Caucasian: 1 (3)
|
31 (79%)
|
Flow cytometry
|
0.73
(0.45-0.1)
|
10 (6.8-13.2)
|
Mexico City, Mexico, 2008
|
1993-2005
|
Hospital Registry
|
34
(1999)
|
24 (70.6)
|
34c
|
Mixed race: 34 (100)
|
NRd
|
NR
|
NR
|
1.3 (0.9-1.8)
|
French Antilles and Cuba, 2009
|
1992-2007 and 2003-2004
|
Hospital registries, primary care, social security departments, patients associations
|
98
(1999)
|
9.8f
|
30.9 (11-74)f
|
Afro-Caribbean: 68 (69.4)
Spain: 30 (30.6)
|
NR
|
NR
|
French Antilles: 1992-1997: 0.22 (0.06-0.38)
1997-2002: 0.18
(0.04-0.32)
2002-2007: 0.2 (0.05-0.35)
|
French Antilles: 4.2 (2.7-5.7)
Cuba: 0.52 (0.39-0.67)
|
Cuba, 2009
|
2003-2004
|
Hospital registries, primary care, national MS registry, patients associations, clinical trials registries
|
58
(1999)
|
51 (87.9)
|
30.5 (11-62)b
|
Caucasian: 31 (53.4)
Mixed race: 18 (31)
Black: 9 (15.5)
|
NR
|
NR
|
0.053
(0.04-0.068)
|
0.52 (0.39-0.67)
|
Panama, 2014
|
2005-2012
|
National registry
|
13
(2006)
|
9 (69.2)
|
35.5 (12.2)a
|
Mixed race: 5 (38.5)
Of African descent: 4 (30.8)
Caucasian: 3 (23.1)
Oriental: 1 (7.6)
|
4/4 (100.0)
|
ELISA
|
0.03 to 0.11 (95% CI not reported)
|
0.29
|
Costa Rica, 2018
|
2011-2015
|
Hospital Registry
|
40
(2006)
|
25 (62.5)
|
35.5 (16-66)b
|
NR
|
15/23 (65.2)
|
ELISA
|
From 0.08 (0.01-0.43) to 0.3 (0.14-0.66)
|
NR
|
AQP4: aquaporin 4; CI: confidence interval; ELISA: enzyme-linked immunosorbent assay; inhab: inhabitants; MOG: myelin oligodendrocyte glycoprotein; MS: multiple sclerosis; NMOSD: neuromyelitis optica spectrum; NR: not reported. a Mean (standard deviation); b Median (range); c Mean (standard deviation not reported); d Antibody determination was not possible locally at the time of the study; e women:men ratio; f Mean and range are reported.
This table does not include the epidemiological study of Venezuela, since the 2015 criteria were used (Table I).
|